a child holding a stuffed animal

R&D insights: The covalent inhibitor revolution

Historically, covalent inhibitors were avoided due to toxic side effects, but the latest breakthroughs in targeting have created a new landscape of opportunities. New breakthrough drugs like ibrutinib, sotorasib, and afatinib are reshaping the landscape of covalent inhibitors. For leaders of R&D, this idea in brief highlights key players, forces, and publication trends that enable better navigation of the opportunities ahead.

fanned image

Download the executive report

Related CAS Insights

Drug Discovery

A review of the global efforts on COVID-19 vaccine development

March 29, 2021

Read article
Drug Discovery

ACE2: Targeting a potentially important receptor in disease pathogenesis

December 15, 2022

Read article
Drug Discovery

ACS webinar on molecular glues and targeted protein degradation

October 12, 2022

Read article

Gain new perspectives for faster progress directly to your inbox.